Filing Details
- Accession Number:
- 0001209191-18-047046
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-08-16 16:23:37
- Reporting Period:
- 2018-08-14
- Accepted Time:
- 2018-08-16 16:23:37
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1131324 | Genomic Health Inc | GHDX | Services-Medical Laboratories (8071) | 770552594 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1333482 | J Kimberly Popovits | 301 Penobscot Dr. Redwood City CA 94063 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2018-08-14 | 8,450 | $51.92 | 228,532 | No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
| Common Stock | Disposition | 2018-08-14 | 50,550 | $52.70 | 177,982 | No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
| Common Stock | Disposition | 2018-08-14 | 1,000 | $53.68 | 176,982 | No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
| No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
| No | 4 | S | Indirect | Held by the Popovits 2010 Trust |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 59,517 | Direct | |
| Common Stock | 12,298 | Indirect | Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits |
| Common Stock | 16,825 | Indirect | Held in trust for the benefit of Ms. Popovits' son, of which Ms. Popovits is trustee. |
Footnotes
- These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 17, 2018.
- Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- Represents weighted average sale price. Actual sale prices ranged from $51.29 to $52.27.
- Represents weighted average sale price. Actual sale prices ranged from $52.30 to $53.26.
- Represents weighted average sale price. Actual sale prices ranged from $53.61 to $54.04.
- Includes an aggregate of 51,204 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Billionaire Hedge Funds
